John I am familiar with this trial at MDA. I am intimately involved in it. I have seen several presentation and trial proposals and cannot comment on specific data. That will happen in time.
The theory that MDA is using is that when the primary tumor is ablated or removed at the presentation of metastatic disease there will in fact be a survival benefit. In the sub setting is whether radiation or surgery is better in this patient cohort among other sub sets.
These questions have never been answered scientifically and the MDA trial is a really good one in my opinion. The schema is excellent in both arms:
Arm 1: ADT+RP/RT on the primary tumor followed by standard of care for monitoring or progression.
Arm 2: ADT followed by standard of care for monitoring or progression.
Brian Chapin is heading this research. The direction of this research is long overdue in my opinion. This will be a main topic at our live meeting in Chicago next week. Good luck in your decision to proceed with the trial or not.
Please note: While I work daily with the medical research teams on PCa, I am not a medical doctor. Please talk to your doctor before making decisions.